Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers
Abstract
:Simple Summary
Abstract
1. Introduction
2. Hepatocellular Carcinoma
2.1. MDR1 in Hepatocellular Carcinoma
2.2. MRP1 in Hepatocellular Carcinoma
2.3. MRP2 in Hepatocellular Carcinoma
2.4. MRP3 in Hepatocellular Carcinoma
2.5. MRP4 in Hepatocellular Carcinoma
2.6. MRP5 in Hepatocellular Carcinoma
2.7. BCRP in Hepatocellular Carcinoma
2.8. Other ABC Pumps in Hepatocellular Carcinoma
3. Biliary Tract Cancer
3.1. MDR1 in Biliary Tract Cancer
3.2. MRP1 in Biliary Tract Cancer
3.3. MRP2 in Biliary Tract Cancer
3.4. MRP3 in Biliary Tract Cancer
3.5. MRP4, MRP5, and MRP6 in Biliary Tract Cancer
3.6. BCRP in Biliary Tract Cancer
4. Hepatoblastoma
4.1. MDR1 in Hepatoblastoma
4.2. MRP1, MRP2, and MRP3 in Hepatoblastoma
4.3. MRP4 and MRP5 in Hepatoblastoma
4.4. BCRP in Hepatoblastoma
4.5. Other ABC Pumps in Hepatoblastoma
5. Gastric Adenocarcinoma
5.1. MDR1 in Gastric Adenocarcinoma
5.2. MRP1 in Gastric Adenocarcinoma
5.3. MRP2 and MRP3 in Gastric Adenocarcinoma
5.4. MRP4 and MRP5 in Gastric Adenocarcinoma
5.5. BCRP in Gastric Adenocarcinoma
6. Pancreatic Ductal Adenocarcinoma
6.1. MDR1 in Pancreatic Ductal Adenocarcinoma
6.2. MRP1 in Pancreatic Ductal Adenocarcinoma
6.3. MRP2 in Pancreatic Ductal Adenocarcinoma
6.4. MRP3 in Pancreatic Ductal Adenocarcinoma
6.5. MRP4 in Pancreatic Ductal Adenocarcinoma
6.6. MRP5 and MRP6 in Pancreatic Ductal Adenocarcinoma
6.7. BCRP in Pancreatic Ductal Adenocarcinoma
7. Colorectal Carcinoma
7.1. MDR1 in Colorectal Carcinoma
7.2. MRP1 in Colorectal Carcinoma
7.3. MRP2 in Colorectal Carcinoma
7.4. MRP3 in Colorectal Carcinoma
7.5. MRP4 in Colorectal Carcinoma
7.6. MRP5 in Colorectal Carcinoma
7.7. BCRP in Colorectal Carcinoma
7.8. Other ABC Pumps in Colorectal Carcinoma
8. Conclusions
Author Contributions
Funding
Conflicts of Interest
Abbreviations
References
- Marin, J.J.G.; Perez-Silva, L.; Macias, R.I.R.; Asensio, M.; Peleteiro-Vigil, A.; Sanchez-Martin, A.; Cives-Losada, C.; Sanchon-Sanchez, P.; Sanchez De Blas, B.; Herraez, E.; et al. Molecular bases of mechanisms accounting for drug resistance in gastric adenocarcinoma. Cancers 2020, 12, 2116. [Google Scholar] [CrossRef] [PubMed]
- Marin, J.J.G.; Macias, R.I.R.; Monte, M.J.; Romero, M.R.; Asensio, M.; Sanchez-Martin, A.; Cives-Losada, C.; Temprano, A.G.; Espinosa-Escudero, R.; Reviejo, M.; et al. Molecular bases of drug resistance in hepatocellular carcinoma. Cancers 2020, 12, 1663. [Google Scholar] [CrossRef]
- Marin, J.J.G.; Sanchon-Sanchez, P.; Cives-Losada, C.; Del Carmen, S.; Gonzalez-Santiago, J.M.; Monte, M.J.; Macias, R.I.R. Novel pharmacological options in the treatment of cholangiocarcinoma: Mechanisms of resistance. Cancers 2021, 13, 2358. [Google Scholar] [CrossRef] [PubMed]
- Dean, M.; Moitra, K.; Allikmets, R. The human ATP-binding cassette (ABC) transporter superfamily. Hum. Mutat. 2022; in press. [Google Scholar] [CrossRef]
- Pavlikova, L.; Seres, M.; Breier, A.; Sulova, Z. The roles of microRNAs in cancer multidrug resistance. Cancers 2022, 14, 1090. [Google Scholar] [CrossRef] [PubMed]
- Di Giacomo, S.; Briz, O.; Monte, M.J.; Sanchez-Vicente, L.; Abete, L.; Lozano, E.; Mazzanti, G.; Di Sotto, A.; Marin, J.J.G. Chemosensitization of hepatocellular carcinoma cells to sorafenib by beta-caryophyllene oxide-induced inhibition of ABC export pumps. Arch. Toxicol. 2019, 93, 623–634. [Google Scholar] [CrossRef] [PubMed]
- Marin, J.J.G.; Romero, M.R.; Herraez, E.; Asensio, M.; Ortiz-Rivero, S.; Sanchez-Martin, A.; Fabris, L.; Briz, O. Mechanisms of pharmacoresistance in hepatocellular carcinoma: New drugs but old problems. Semin. Liver Dis. 2022, 42, 87–103. [Google Scholar] [CrossRef] [PubMed]
- Gao, B.; Yang, F.M.; Yu, Z.T.; Li, R.; Xie, F.; Chen, J.; Luo, H.J.; Zhang, J.C. Relationship between the expression of MDR1 in hepatocellular cancer and its biological behaviors. Int. J. Clin. Exp. Pathol. 2015, 8, 6995–7001. [Google Scholar] [PubMed]
- Estevinho, M.M.; Fernandes, C.; Silva, J.C.; Gomes, A.C.; Afecto, E.; Correia, J.; Carvalho, J. Role of ATP-binding cassette transporters in sorafenib therapy for hepatocellular carcinoma: An overview. Curr. Drug Targets 2022, 23, 21–32. [Google Scholar] [CrossRef] [PubMed]
- Asghar, U.; Meyer, T. Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J. Hepatol. 2012, 56, 686–695. [Google Scholar] [CrossRef]
- Tandia, M.; Mhiri, A.; Paule, B.; Saffroy, R.; Cailliez, V.; Noe, G.; Farinotti, R.; Bonhomme-Faivre, L. Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): Monocentric study. Cancer Chemother. Pharm. 2017, 79, 759–766. [Google Scholar] [CrossRef] [PubMed]
- Cheung, S.T.; Cheung, P.F.; Cheng, C.K.; Wong, N.C.; Fan, S.T. Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance. Gastroenterology 2011, 140, 344–355. [Google Scholar] [CrossRef] [PubMed]
- Chang, Y.S.; Su, C.W.; Chen, S.C.; Chen, Y.Y.; Liang, Y.J.; Wu, J.C. Upregulation of USP22 and ABCC1 during sorafenib treatment of hepatocellular carcinoma contribute to development of resistance. Cells 2022, 11, 634. [Google Scholar] [CrossRef] [PubMed]
- Shibayama, Y.; Nakano, K.; Maeda, H.; Taguchi, M.; Ikeda, R.; Sugawara, M.; Iseki, K.; Takeda, Y.; Yamada, K. Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. Biol. Pharm. Bull. 2011, 34, 433–435. [Google Scholar] [CrossRef] [PubMed]
- Tomonari, T.; Takeishi, S.; Taniguchi, T.; Tanaka, T.; Tanaka, H.; Fujimoto, S.; Kimura, T.; Okamoto, K.; Miyamoto, H.; Muguruma, N.; et al. MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma. Oncotarget 2016, 7, 7207–7215. [Google Scholar] [CrossRef] [PubMed]
- Wakamatsu, T.; Nakahashi, Y.; Hachimine, D.; Seki, T.; Okazaki, K. The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int. J. Oncol. 2007, 31, 1465–1472. [Google Scholar] [CrossRef]
- Rius, M.; Nies, A.T.; Hummel-Eisenbeiss, J.; Jedlitschky, G.; Keppler, D. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 2003, 38, 374–384. [Google Scholar] [CrossRef]
- Borel, F.; Han, R.; Visser, A.; Petry, H.; van Deventer, S.J.; Jansen, P.L.; Konstantinova, P.; Reseau Centre de Ressources Biologiques Foie, F. Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology 2012, 55, 821–832. [Google Scholar] [CrossRef]
- Wang, X.B.; Wang, S.S.; Zhang, Q.F.; Liu, M.; Li, H.L.; Liu, Y.; Wang, J.N.; Zheng, F.; Guo, L.Y.; Xiang, J.Z. Inhibition of tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug resistant human hepatocellular carcinoma cells. Oncol. Rep. 2010, 23, 211–215. [Google Scholar]
- Hu, C.; Li, H.; Li, J.; Zhu, Z.; Yin, S.; Hao, X.; Yao, M.; Zheng, S.; Gu, J. Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis 2008, 29, 2289–2297. [Google Scholar] [CrossRef]
- Huang, W.C.; Hsieh, Y.L.; Hung, C.M.; Chien, P.H.; Chien, Y.F.; Chen, L.C.; Tu, C.Y.; Chen, C.H.; Hsu, S.C.; Lin, Y.M.; et al. BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib. PLoS ONE 2013, 8, e83627. [Google Scholar] [CrossRef] [PubMed]
- Fung, S.W.; Cheung, P.F.; Yip, C.W.; Ng, L.W.; Cheung, T.T.; Chong, C.C.; Lee, C.; Lai, P.B.; Chan, A.W.; Tsao, G.S.; et al. The ATP-binding cassette transporter ABCF1 is a hepatic oncofetal protein that promotes chemoresistance, EMT and cancer stemness in hepatocellular carcinoma. Cancer Lett. 2019, 457, 98–109. [Google Scholar] [CrossRef] [PubMed]
- Thiebaut, F.; Tsuruo, T.; Hamada, H.; Gottesman, M.M.; Pastan, I.; Willingham, M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 1987, 84, 7735–7738. [Google Scholar] [CrossRef] [PubMed]
- Chenivesse, X.; Franco, D.; Brechot, C. MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis. J. Hepatol. 1993, 18, 168–172. [Google Scholar] [CrossRef]
- Ng, I.O.; Liu, C.L.; Fan, S.T.; Ng, M. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. Am. J. Clin. Pathol. 2000, 113, 355–363. [Google Scholar] [CrossRef]
- Minemura, M.; Tanimura, H.; Tabor, E. Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines. Int. J. Oncol. 1999, 15, 559–563. [Google Scholar] [CrossRef]
- Kort, A.; Durmus, S.; Sparidans, R.W.; Wagenaar, E.; Beijnen, J.H.; Schinkel, A.H. Brain and testis accumulation of regorafenib is restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1). Pharm. Res. 2015, 32, 2205–2216. [Google Scholar] [CrossRef]
- Shumaker, R.C.; Aluri, J.; Fan, J.; Martinez, G.; Thompson, G.A.; Ren, M. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults. Clin. Drug Investig. 2014, 34, 651–659. [Google Scholar] [CrossRef]
- Keppler, D. Multidrug resistance proteins (MRPs, ABCCs): Importance for pathophysiology and drug therapy. In Drug Transporters. Handbook of Experimental Pharmacology; Springer: Berlin/Heidelberg, Germany, 2011; pp. 299–323. [Google Scholar] [CrossRef]
- Hoffmann, K.; Shibo, L.; Xiao, Z.; Longerich, T.; Buchler, M.W.; Schemmer, P. Correlation of gene expression of ATP-binding cassette protein and tyrosine kinase signaling pathway in patients with hepatocellular carcinoma. Anticancer Res. 2011, 31, 3883–3890. [Google Scholar]
- Bonin, S.; Pascolo, L.; Croce, L.S.; Stanta, G.; Tiribelli, C. Gene expression of ABC proteins in hepatocellular carcinoma, perineoplastic tissue, and liver diseases. Mol. Med. 2002, 8, 318–325. [Google Scholar] [CrossRef]
- Nies, A.T.; Konig, J.; Pfannschmidt, M.; Klar, E.; Hofmann, W.J.; Keppler, D. Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int. J. Cancer 2001, 94, 492–499. [Google Scholar] [CrossRef] [PubMed]
- He, S.M.; Li, R.; Kanwar, J.R.; Zhou, S.F. Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1). Curr. Med. Chem. 2011, 18, 439–481. [Google Scholar] [CrossRef]
- Nies, A.T.; Keppler, D. The apical conjugate efflux pump ABCC2 (MRP2). Pflug. Arch. 2007, 453, 643–659. [Google Scholar] [CrossRef] [PubMed]
- Zollner, G.; Wagner, M.; Fickert, P.; Silbert, D.; Fuchsbichler, A.; Zatloukal, K.; Denk, H.; Trauner, M. Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int. 2005, 25, 367–379. [Google Scholar] [CrossRef] [PubMed]
- Vasilyeva, A.; Durmus, S.; Li, L.; Wagenaar, E.; Hu, S.; Gibson, A.A.; Panetta, J.C.; Mani, S.; Sparreboom, A.; Baker, S.D.; et al. Hepatocellular shuttling and recirculation of sorafenib-glucuronide is dependent on Abcc2, Abcc3, and Oatp1a/1b. Cancer Res. 2015, 75, 2729–2736. [Google Scholar] [CrossRef]
- Ohya, H.; Shibayama, Y.; Ogura, J.; Narumi, K.; Kobayashi, M.; Iseki, K. Regorafenib is transported by the organic anion transporter 1B1 and the multidrug resistance protein 2. Biol. Pharm. Bull. 2015, 38, 582–586. [Google Scholar] [CrossRef]
- Lacy, S.; Hsu, B.; Miles, D.; Aftab, D.; Wang, R.; Nguyen, L. Metabolism and disposition of cabozantinib in healthy male volunteers and pharmacologic characterization of its major metabolites. Drug Metab. Dispos. 2015, 43, 1190–1207. [Google Scholar] [CrossRef]
- Ozeki, T.; Nagahama, M.; Fujita, K.; Suzuki, A.; Sugino, K.; Ito, K.; Miura, M. Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer. Sci. Rep. 2019, 9, 5404. [Google Scholar] [CrossRef]
- Cirqueira, C.S.; Felipe-Silva, A.S.; Wakamatsu, A.; Marins, L.V.; Rocha, E.C.; de Mello, E.S.; Alves, V.A.F. Immunohistochemical assessment of the expression of biliary transportation proteins MRP2 and MRP3 in hepatocellular carcinoma and in cholangiocarcinoma. Pathol. Oncol. Res. 2019, 25, 1363–1371. [Google Scholar] [CrossRef]
- Martinez-Becerra, P.; Vaquero, J.; Romero, M.R.; Lozano, E.; Anadon, C.; Macias, R.I.; Serrano, M.A.; Grane-Boladeras, N.; Munoz-Bellvis, L.; Alvarez, L.; et al. No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors. Mol. Pharm. 2012, 9, 1693–1704. [Google Scholar] [CrossRef]
- Jouan, E.; Le Vee, M.; Denizot, C.; Parmentier, Y.; Fardel, O. Drug transporter expression and activity in human hepatoma HuH-7 cells. Pharmaceutics 2016, 9, 3. [Google Scholar] [CrossRef] [PubMed]
- Le Vee, M.; Noel, G.; Jouan, E.; Stieger, B.; Fardel, O. Polarized expression of drug transporters in differentiated human hepatoma HepaRG cells. Toxicol. In Vitro 2013, 27, 1979–1986. [Google Scholar] [CrossRef] [PubMed]
- Kool, M.; de Haas, M.; Scheffer, G.L.; Scheper, R.J.; van Eijk, M.J.; Juijn, J.A.; Baas, F.; Borst, P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997, 57, 3537–3547. [Google Scholar]
- Moustafa, M.A.; Ogino, D.; Nishimura, M.; Ueda, N.; Naito, S.; Furukawa, M.; Uchida, T.; Ikai, I.; Sawada, H.; Fukumoto, M. Comparative analysis of ATP-binding cassette (ABC) transporter gene expression levels in peripheral blood leukocytes and in liver with hepatocellular carcinoma. Cancer Sci. 2004, 95, 530–536. [Google Scholar] [CrossRef] [PubMed]
- Jedlitschky, G.; Burchell, B.; Keppler, D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J. Biol. Chem. 2000, 275, 30069–30074. [Google Scholar] [CrossRef]
- Jilek, J.L.; Tu, M.J.; Zhang, C.; Yu, A.M. Pharmacokinetic and pharmacodynamic factors contribute to synergism between Let-7c-5p and 5-fluorouracil in inhibiting hepatocellular carcinoma cell viability. Drug Metab. Dispos. 2020, 48, 1257–1263. [Google Scholar] [CrossRef] [PubMed]
- Maliepaard, M.; Scheffer, G.L.; Faneyte, I.F.; van Gastelen, M.A.; Pijnenborg, A.C.; Schinkel, A.H.; van De Vijver, M.J.; Scheper, R.J.; Schellens, J.H. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001, 61, 3458–3464. [Google Scholar]
- Sukowati, C.H.; Rosso, N.; Pascut, D.; Anfuso, B.; Torre, G.; Francalanci, P.; Croce, L.S.; Tiribelli, C. Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma. BMC Gastroenterol. 2012, 12, 160. [Google Scholar] [CrossRef]
- Chen, Y.L.; Chen, P.M.; Lin, P.Y.; Hsiau, Y.T.; Chu, P.Y. ABCG2 overexpression confers poor outcomes in hepatocellular carcinoma of elderly patients. Anticancer Res. 2016, 36, 2983–2988. [Google Scholar]
- Xie, Z.Y.; Liu, M.S.; Zhang, C.; Cai, P.C.; Xiao, Z.H.; Wang, F.F. Aspirin enhances the sensitivity of hepatocellular carcinoma side population cells to doxorubicin via miR-491/ABCG2. Biosci. Rep. 2018, 38, BSR20180854. [Google Scholar] [CrossRef]
- Zhang, G.; Wang, Z.; Luo, W.; Jiao, H.; Wu, J.; Jiang, C. Expression of potential cancer stem cell marker ABCG2 is associated with malignant behaviors of hepatocellular carcinoma. Gastroenterol. Res. Pract. 2013, 2013, 782581. [Google Scholar] [CrossRef] [PubMed]
- Tsunedomi, R.; Yoshimura, K.; Kimura, Y.; Nishiyama, M.; Fujiwara, N.; Matsukuma, S.; Kanekiyo, S.; Matsui, H.; Shindo, Y.; Watanabe, Y.; et al. Elevated expression of RAB3B plays important roles in chemoresistance and metastatic potential of hepatoma cells. BMC Cancer 2022, 22, 260. [Google Scholar] [CrossRef] [PubMed]
- Namisaki, T.; Schaeffeler, E.; Fukui, H.; Yoshiji, H.; Nakajima, Y.; Fritz, P.; Schwab, M.; Nies, A.T. Differential expression of drug uptake and efflux transporters in Japanese patients with hepatocellular carcinoma. Drug Metab. Dispos. 2014, 42, 2033–2040. [Google Scholar] [CrossRef] [PubMed]
- Agarwal, S.; Sane, R.; Ohlfest, J.R.; Elmquist, W.F. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J. Pharm. Exp. 2011, 336, 223–233. [Google Scholar] [CrossRef]
- Briz, O.; Perez-Silva, L.; Al-Abdulla, R.; Abete, L.; Reviejo, M.; Romero, M.R.; Marin, J.J.G. What “The Cancer Genome Atlas” database tells us about the role of ATP-binding cassette (ABC) proteins in chemoresistance to anticancer drugs. Expert Opin. Drug Metab. Toxicol. 2019, 15, 577–593. [Google Scholar] [CrossRef]
- Cheung, P.F.; Cheung, T.T.; Yip, C.W.; Ng, L.W.; Fung, S.W.; Lo, C.M.; Fan, S.T.; Cheung, S.T. Hepatic cancer stem cell marker granulin-epithelin precursor and beta-catenin expression associate with recurrence in hepatocellular carcinoma. Oncotarget 2016, 7, 21644–21657. [Google Scholar] [CrossRef]
- Marin, J.J.G.; Prete, M.G.; Lamarca, A.; Tavolari, S.; Landa-Magdalena, A.; Brandi, G.; Segatto, O.; Vogel, A.; Macias, R.I.R.; Rodrigues, P.M.; et al. Current and novel therapeutic opportunities for systemic therapy in biliary cancer. Br. J. Cancer 2020, 123, 1047–1059. [Google Scholar] [CrossRef]
- Marin, J.J.G.; Macias, R.I.R.; Cives-Losada, C.; Peleteiro-Vigil, A.; Herraez, E.; Lozano, E. Plasma membrane transporters as biomarkers and molecular targets in cholangiocarcinoma. Cells 2020, 9, 498. [Google Scholar] [CrossRef]
- Wang, H.; Zhan, M.; Xu, S.W.; Chen, W.; Long, M.M.; Shi, Y.H.; Liu, Q.; Mohan, M.; Wang, J. miR-218-5p restores sensitivity to gemcitabine through PRKCE/MDR1 axis in gallbladder cancer. Cell Death Dis. 2017, 8, e2770. [Google Scholar] [CrossRef]
- Wattanawongdon, W.; Hahnvajanawong, C.; Namwat, N.; Kanchanawat, S.; Boonmars, T.; Jearanaikoon, P.; Leelayuwat, C.; Techasen, A.; Seubwai, W. Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. Int. J. Oncol. 2015, 47, 398–410. [Google Scholar] [CrossRef]
- Wu, W.R.; Zhang, R.; Shi, X.D.; Zhu, M.S.; Xu, L.B.; Zeng, H.; Liu, C. Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro. Oncol. Rep. 2014, 31, 2515–2524. [Google Scholar] [CrossRef]
- Srimunta, U.; Sawanyawisuth, K.; Kraiklang, R.; Pairojkul, C.; Puapairoj, A.; Titipungul, T.; Hahnvajanawong, C.; Tassaneeyakul, W.; Wongkham, C.; Wongkham, S.; et al. High expression of ABCC1 indicates poor prognosis in intrahepatic cholangiocarcinoma. Asian Pac. J. Cancer Prev. 2012, 13, 125–130. [Google Scholar] [PubMed]
- Zhan, M.; Zhao, X.; Wang, H.; Chen, W.; Xu, S.; Wang, W.; Shen, H.; Huang, S.; Wang, J. miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1. Tumour Biol. 2016, 37, 10553–10562. [Google Scholar] [CrossRef] [PubMed]
- Lozano, E.; Asensio, M.; Perez-Silva, L.; Banales, J.M.; Briz, O.; Marin, J.J.G. MRP3-mediated chemoresistance in cholangiocarcinoma: Target for chemosensitization through restoring SOX17 expression. Hepatology 2020, 72, 949–964. [Google Scholar] [CrossRef] [PubMed]
- Yang, J.; Sontag, D.; Gong, Y.; Minuk, G.Y. Enhanced gemcitabine cytotoxicity with knockdown of multidrug resistance protein genes in human cholangiocarcinoma cell lines. J. Gastroenterol. Hepatol. 2021, 36, 1103–1109. [Google Scholar] [CrossRef] [PubMed]
- Sribenja, S.; Natthasirikul, N.; Vaeteewoottacharn, K.; Sawanyawisuth, K.; Wongkham, C.; Jearanaikoon, P.; Wongkham, S. Thymosin beta10 as a predictive biomarker of response to 5-fluorouracil chemotherapy in cholangiocarcinoma. Ann. Hepatol. 2016, 15, 577–585. [Google Scholar]
- Pavelic, Z.P.; Reising, J.; Pavelic, L.; Kelley, D.J.; Stambrook, P.J.; Gluckman, J.L. Detection of P-glycoprotein with four monoclonal antibodies in normal and tumor tissues. Arch. Otolaryngol. Head Neck Surg. 1993, 119, 753–757. [Google Scholar] [CrossRef]
- Wang, B.L.; Zhai, H.Y.; Chen, B.Y.; Zhai, S.P.; Yang, H.Y.; Chen, X.P.; Zhao, W.T.; Meng, L. Clinical relationship between MDR1 gene and gallbladder cancer. Hepatobiliary Pancreat. Dis. Int. 2004, 3, 296–299. [Google Scholar]
- Marin, J.J.G.; Lozano, E.; Briz, O.; Al-Abdulla, R.; Serrano, M.A.; Macias, R.I.R. Molecular bases of chemoresistance in cholangiocarcinoma. Curr. Drug Targets 2017, 18, 889–900. [Google Scholar] [CrossRef]
- Rost, D.; Konig, J.; Weiss, G.; Klar, E.; Stremmel, W.; Keppler, D. Expression and localization of the multidrug resistance proteins MRP2 and MRP3 in human gallbladder epithelia. Gastroenterology 2001, 121, 1203–1208. [Google Scholar] [CrossRef]
- Pangestu, N.S.; Chueakwon, P.; Talabnin, K.; Khiaowichit, J.; Talabnin, C. RNF43 overexpression attenuates the Wnt/beta-catenin signalling pathway to suppress tumour progression in cholangiocarcinoma. Oncol. Lett. 2021, 22, 846. [Google Scholar] [CrossRef]
- Rau, S.; Autschbach, F.; Riedel, H.D.; Konig, J.; Kulaksiz, H.; Stiehl, A.; Riemann, J.F.; Rost, D. Expression of the multidrug resistance proteins MRP2 and MRP3 in human cholangiocellular carcinomas. Eur. J. Clin. Investig. 2008, 38, 134–142. [Google Scholar] [CrossRef] [PubMed]
- Kim, H.S.; Kim, N.C.; Chae, K.H.; Kim, G.; Park, W.S.; Park, Y.K.; Kim, Y.W. Expression of multidrug resistance-associated protein 2 in human gallbladder carcinoma. BioMed Res. Int. 2013, 2013, 527534. [Google Scholar] [CrossRef]
- Tepsiri, N.; Chaturat, L.; Sripa, B.; Namwat, W.; Wongkham, S.; Bhudhisawasdi, V.; Tassaneeyakul, W. Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. World J. Gastroenterol. 2005, 11, 2748–2753. [Google Scholar] [CrossRef] [PubMed]
- Samatiwat, P.; Prawan, A.; Senggunprai, L.; Kukongviriyapan, U.; Kukongviriyapan, V. Nrf2 inhibition sensitizes cholangiocarcinoma cells to cytotoxic and antiproliferative activities of chemotherapeutic agents. Tumour Biol. 2016, 37, 11495–11507. [Google Scholar] [CrossRef] [PubMed]
- Cui, Y.; Konig, J.; Buchholz, J.K.; Spring, H.; Leier, I.; Keppler, D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharm. 1999, 55, 929–937. [Google Scholar]
- Myint, K.; Biswas, R.; Li, Y.; Jong, N.; Jamieson, S.; Liu, J.; Han, C.; Squire, C.; Merien, F.; Lu, J.; et al. Identification of MRP2 as a targetable factor limiting oxaliplatin accumulation and response in gastrointestinal cancer. Sci. Rep. 2019, 9, 2245. [Google Scholar] [CrossRef]
- Liu, J.; Hu, G.; Gong, Y.; Yu, Q.; He, B.; Li, W.; He, Z.; Hao, W.; He, Z.; Liu, Y. Silencing of TRPM8 inhibits aggressive tumor phenotypes and enhances gemcitabine sensitivity in pancreatic cancer. Pancreatology 2018, 18, 935–944. [Google Scholar] [CrossRef]
- Scheffer, G.L.; Kool, M.; de Haas, M.; de Vree, J.M.; Pijnenborg, A.C.; Bosman, D.K.; Elferink, R.P.; van der Valk, P.; Borst, P.; Scheper, R.J. Tissue distribution and induction of human multidrug resistant protein 3. Lab. Investig. 2002, 82, 193–201. [Google Scholar] [CrossRef]
- Wang, J.; Zhang, M.; Zhang, L.; Cai, H.; Zhou, S.; Zhang, J.; Wang, Y. Correlation of Nrf2, HO-1, and MRP3 in gallbladder cancer and their relationships to clinicopathologic features and survival. J. Surg. Res. 2010, 164, e99–e105. [Google Scholar] [CrossRef]
- Kurzawski, M.; Dziedziejko, V.; Post, M.; Wojcicki, M.; Urasinska, E.; Mietkiewski, J.; Drozdzik, M. Expression of genes involved in xenobiotic metabolism and transport in end-stage liver disease: Up-regulation of ABCC4 and CYP1B1. Pharm. Rep. 2012, 64, 927–939. [Google Scholar] [CrossRef]
- Kool, M.; van der Linden, M.; de Haas, M.; Baas, F.; Borst, P. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res. 1999, 59, 175–182. [Google Scholar] [PubMed]
- Vander Borght, S.; Libbrecht, L.; Katoonizadeh, A.; van Pelt, J.; Cassiman, D.; Nevens, F.; Van Lommel, A.; Petersen, B.E.; Fevery, J.; Jansen, P.L.; et al. Breast cancer resistance protein (BCRP/ABCG2) is expressed by progenitor cells/reactive ductules and hepatocytes and its expression pattern is influenced by disease etiology and species type: Possible functional consequences. J. Histochem. Cytochem. 2006, 54, 1051–1059. [Google Scholar] [CrossRef] [PubMed]
- Aust, S.; Obrist, P.; Jaeger, W.; Klimpfinger, M.; Tucek, G.; Wrba, F.; Penner, E.; Thalhammer, T. Subcellular localization of the ABCG2 transporter in normal and malignant human gallbladder epithelium. Lab. Investig. 2004, 84, 1024–1036. [Google Scholar] [CrossRef]
- Meyers, R.L.; Maibach, R.; Hiyama, E.; Haberle, B.; Krailo, M.; Rangaswami, A.; Aronson, D.C.; Malogolowkin, M.H.; Perilongo, G.; von Schweinitz, D.; et al. Risk-stratified staging in paediatric hepatoblastoma: A unified analysis from the Children’s Hepatic tumors International Collaboration. Lancet Oncol. 2017, 18, 122–131. [Google Scholar] [CrossRef]
- De Ioris, M.; Brugieres, L.; Zimmermann, A.; Keeling, J.; Brock, P.; Maibach, R.; Pritchard, J.; Shafford, L.; Zsiros, J.; Czaudzerna, P.; et al. Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: The SIOPEL group experience. Eur. J. Cancer 2008, 44, 545–550. [Google Scholar] [CrossRef]
- Marin, J.J.G.; Cives-Losada, C.; Asensio, M.; Lozano, E.; Briz, O.; Macias, R.I.R. Mechanisms of anticancer drug resistance in hepatoblastoma. Cancers 2019, 11, 407. [Google Scholar] [CrossRef]
- Chen, Y.B.; Yan, M.L.; Gong, J.P.; Xia, R.P.; Liu, L.X.; Li, N.; Lu, S.C.; Zhang, J.G.; Zeng, D.B.; Xie, J.G.; et al. Establishment of hepatocellular carcinoma multidrug resistant monoclone cell line HepG2/mdr1. Chin. Med. J. 2007, 120, 703–707. [Google Scholar] [CrossRef]
- Korita, P.V.; Wakai, T.; Shirai, Y.; Matsuda, Y.; Sakata, J.; Takamura, M.; Yano, M.; Sanpei, A.; Aoyagi, Y.; Hatakeyama, K.; et al. Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma. Oncol. Rep. 2010, 23, 965–972. [Google Scholar] [CrossRef]
- Oue, T.; Yoneda, A.; Uehara, S.; Yamanaka, H.; Fukuzawa, M. Increased expression of multidrug resistance-associated genes after chemotherapy in pediatric solid malignancies. J. Pediatr. Surg. 2009, 44, 377–380. [Google Scholar] [CrossRef]
- Warmann, S.; Hunger, M.; Teichmann, B.; Flemming, P.; Gratz, K.F.; Fuchs, J. The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: Clinical course and in vivo model. Cancer 2002, 95, 1795–1801. [Google Scholar] [CrossRef]
- Liu, T.; Wei, R.; Zhang, Y.; Chen, W.; Liu, H. Association between NF-kappaB expression and drug resistance of liver cancer. Oncol. Lett. 2019, 17, 1030–1034. [Google Scholar] [CrossRef] [PubMed]
- Bader, P.; Fuchs, J.; Wenderoth, M.; von Schweinitz, D.; Niethammer, D.; Beck, J.F. Altered expression of resistance associated genes in hepatoblastoma xenografts incorporated into mice following treatment with adriamycin or cisplatin. Anticancer Res. 1998, 18, 3127–3132. [Google Scholar] [PubMed]
- Warmann, S.W.; Heitmann, H.; Teichmann, B.; Gratz, K.F.; Ruck, P.; Hunger, M.; Fuchs, J. Effects of P-glycoprotein modulation on the chemotherapy of xenotransplanted human hepatoblastoma. Pediatr. Hematol. Oncol. 2005, 22, 373–386. [Google Scholar] [CrossRef] [PubMed]
- Pascolo, L.; Fernetti, C.; Pirulli, D.; Bogoni, S.; Garcia-Mediavilla, M.V.; Spano, A.; Puzzer, D.; Tiribelli, C.; Amoroso, A.; Crovella, S. Detection of MRP1 mRNA in human tumors and tumor cell lines by in situ RT-PCR. Biochem. Biophys. Res. Commun. 2000, 275, 466–471. [Google Scholar] [CrossRef]
- Eicher, C.; Dewerth, A.; Kirchner, B.; Warmann, S.W.; Fuchs, J.; Armeanu-Ebinger, S. Development of a drug resistance model for hepatoblastoma. Int. J. Oncol. 2011, 38, 447–454. [Google Scholar] [CrossRef]
- Vander Borght, S.; van Pelt, J.; van Malenstein, H.; Cassiman, D.; Renard, M.; Verslype, C.; Libbrecht, L.; Roskams, T.A. Up-regulation of breast cancer resistance protein expression in hepatoblastoma following chemotherapy: A study in patients and in vitro. Hepatol. Res. 2008, 38, 1112–1121. [Google Scholar] [CrossRef]
- Su, Z.; Liu, G.; Fang, T.; Wang, Y.; Zhang, H.; Yang, S.; Wei, J.; Lv, Z.; Tan, L.; Liu, J. Silencing MRP1-4 genes by RNA interference enhances sensitivity of human hepatoma cells to chemotherapy. Am. J. Transl. Res. 2016, 8, 2790–2802. [Google Scholar]
- Liu, X.Y.; Liu, S.P.; Jiang, J.; Zhang, X.; Zhang, T. Inhibition of the JNK signaling pathway increases sensitivity of hepatocellular carcinoma cells to cisplatin by down-regulating expression of P-glycoprotein. Eur. Rev. Med. Pharmacol. Sci. 2016, 20, 1098–1108. [Google Scholar]
- Schrenk, D.; Baus, P.R.; Ermel, N.; Klein, C.; Vorderstemann, B.; Kauffmann, H.M. Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol. Lett. 2001, 120, 51–57. [Google Scholar] [CrossRef]
- Lagas, J.S.; Fan, L.; Wagenaar, E.; Vlaming, M.L.; van Tellingen, O.; Beijnen, J.H.; Schinkel, A.H. P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clin. Cancer Res. 2010, 16, 130–140. [Google Scholar] [CrossRef]
- Liu, W.; Song, H.; Chen, Q.; Xu, C.; Zhang, W.; Liu, Y.; Wang, B.; Xu, D.; Lu, M.; Yang, D.; et al. Multidrug resistance protein 4 is a critical protein associated with the antiviral efficacy of nucleos(t)ide analogues. Liver Int. 2016, 36, 1284–1294. [Google Scholar] [CrossRef]
- Pratt, S.; Shepard, R.L.; Kandasamy, R.A.; Johnston, P.A.; Perry, W., 3rd; Dantzig, A.H. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol. Cancer 2005, 4, 855–863. [Google Scholar] [CrossRef]
- Borst, P.; de Wolf, C.; van de Wetering, K. Multidrug resistance-associated proteins 3, 4, and 5. Pflug. Arch. 2007, 453, 661–673. [Google Scholar] [CrossRef] [PubMed]
- Lee, G.; Piquette-Miller, M. Influence of IL-6 on MDR and MRP-mediated multidrug resistance in human hepatoma cells. Can. J. Physiol. Pharm. 2001, 79, 876–884. [Google Scholar] [CrossRef]
- Belinsky, M.G.; Chen, Z.S.; Shchaveleva, I.; Zeng, H.; Kruh, G.D. Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002, 62, 6172–6177. [Google Scholar] [PubMed]
- Hopper-Borge, E.; Xu, X.; Shen, T.; Shi, Z.; Chen, Z.S.; Kruh, G.D. Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 2009, 69, 178–184. [Google Scholar] [CrossRef]
- Joshi, S.S.; Badgwell, B.D. Current treatment and recent progress in gastric cancer. CA A Cancer J. Clin. 2021, 71, 264–279. [Google Scholar] [CrossRef]
- Al-Batran, S.E.; Homann, N.; Pauligk, C.; Goetze, T.O.; Meiler, J.; Kasper, S.; Kopp, H.G.; Mayer, F.; Haag, G.M.; Luley, K.; et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2/3 trial. Lancet 2019, 393, 1948–1957. [Google Scholar] [CrossRef]
- Elimova, E.; Janjigian, Y.Y.; Mulcahy, M.; Catenacci, D.V.; Blum, M.A.; Almhanna, K.; Hecht, J.R.; Ajani, J.A. It is time to stop using epirubicin to treat any patient with gastroesophageal adenocarcinoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2017, 35, 475–477. [Google Scholar] [CrossRef]
- Ivey, A.; Pratt, H.; Boone, B.A. Molecular pathogenesis and emerging targets of gastric adenocarcinoma. J. Surg. Oncol. 2022, 125, 1079–1095. [Google Scholar] [CrossRef] [PubMed]
- Marin, J.J.; Romero, M.R.; Blazquez, A.G.; Herraez, E.; Keck, E.; Briz, O. Importance and limitations of chemotherapy among the available treatments for gastrointestinal tumours. Anti-Cancer Agents Med. Chem. 2009, 9, 162–184. [Google Scholar] [CrossRef] [PubMed]
- Zhai, J.; Shen, J.; Xie, G.; Wu, J.; He, M.; Gao, L.; Zhang, Y.; Yao, X.; Shen, L. Cancer-associated fibroblasts-derived IL-8 mediates resistance to cisplatin in human gastric cancer. Cancer Lett. 2019, 454, 37–43. [Google Scholar] [CrossRef] [PubMed]
- Danza, K.; Silvestris, N.; Simone, G.; Signorile, M.; Saragoni, L.; Brunetti, O.; Monti, M.; Mazzotta, A.; De Summa, S.; Mangia, A.; et al. Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance. Cancer Biol. Ther. 2016, 17, 400–406. [Google Scholar] [CrossRef]
- Wu, X.; Zheng, Y.; Han, B.; Dong, X. Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361. Biomed. Pharmacother. 2018, 99, 832–838. [Google Scholar] [CrossRef]
- Mo, D.; Fang, H.; Niu, K.; Liu, J.; Wu, M.; Li, S.; Zhu, T.; Aleskandarany, M.A.; Arora, A.; Lobo, D.N.; et al. Human helicase RECQL4 drives cisplatin resistance in gastric cancer by activating an AKT-YB1-MDR1 signaling pathway. Cancer Res. 2016, 76, 3057–3066. [Google Scholar] [CrossRef]
- Felipe, A.V.; Oliveira, J.; Moraes, A.A.; Franca, J.P.; Silva, T.D.; Forones, N.M. Reversal of multidrug resistance in an epirubicin-resistant gastric cancer cell subline. Asian Pac. J. Cancer Prev. 2018, 19, 1237–1242. [Google Scholar] [CrossRef]
- Wongsirisin, P.; Limpakan Yamada, S.; Yodkeeree, S.; Punfa, W.; Limtrakul, P. Association of DNA repair and drug transporter in relation to chemosensitivity in primary culture of Thai gastric cancer patients. Biol. Pharm. Bull. 2018, 41, 360–367. [Google Scholar] [CrossRef]
- Zhang, G.; Wang, Z.; Qian, F.; Zhao, C.; Sun, C. Silencing of the ABCC4 gene by RNA interference reverses multidrug resistance in human gastric cancer. Oncol. Rep. 2015, 33, 1147–1154. [Google Scholar] [CrossRef]
- Zhang, Y.H.; Wu, Q.; Xiao, X.Y.; Li, D.W.; Wang, X.P. Silencing MRP4 by small interfering RNA reverses acquired DDP resistance of gastric cancer cell. Cancer Lett. 2010, 291, 76–82. [Google Scholar] [CrossRef]
- Furmanski, B.D.; Hu, S.; Fujita, K.I.; Li, L.; Gibson, A.A.; Janke, L.J.; Williams, R.T.; Schuetz, J.D.; Sparreboom, A.; Baker, S.D. Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib. Clin. Cancer Res. 2013, 19, 4359–4370. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Q.; Li, K.; Xu, J.H.; Zhao, C.G.; Gao, Q.; Wu, B.; Liu, X.Y. Role of ABCG2 expression driven by cisplatin in platinum-containing chemotherapy for gastric cancer. World J. Gastroenterol. 2013, 19, 6630–6636. [Google Scholar] [CrossRef]
- Yu, B.; Gu, D.; Zhang, X.; Liu, B.; Xie, J. The role of GLI2-ABCG2 signaling axis for 5Fu resistance in gastric cancer. J. Genet. Genom. 2017, 44, 375–383. [Google Scholar] [CrossRef] [PubMed]
- Fojo, A.T.; Ueda, K.; Slamon, D.J.; Poplack, D.G.; Gottesman, M.M.; Pastan, I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. USA 1987, 84, 265–269. [Google Scholar] [CrossRef] [PubMed]
- Rocco, A.; Compare, D.; Liguori, E.; Cianflone, A.; Pirozzi, G.; Tirino, V.; Bertoni, A.; Santoriello, M.; Garbi, C.; D’Armiento, M.; et al. MDR1-P-glycoprotein behaves as an oncofetal protein that promotes cell survival in gastric cancer cells. Lab. Investig. 2012, 92, 1407–1418. [Google Scholar] [CrossRef]
- Gurel, S.; Yerci, O.; Filiz, G.; Dolar, E.; Yilmazlar, T.; Nak, S.G.; Gulten, M.; Zorluoglu, A.; Memik, F. High expression of multidrug resistance-1 (MDR-1) and its relationship with multiple prognostic factors in gastric carcinomas in patients in Turkey. J. Int. Med. Res. 1999, 27, 79–84. [Google Scholar] [CrossRef]
- Wallner, J.; Depisch, D.; Gsur, A.; Gotzl, M.; Haider, K.; Pirker, R. MDR1 gene expression and its clinical relevance in primary gastric carcinomas. Cancer 1993, 71, 667–671. [Google Scholar] [CrossRef]
- de Oliveira, J.; Felipe, A.V.; Neto, R.A.; Oshima, C.T.; de Souza Silva, M.; Forones, N.M. Association between ABCB1 immunohistochemical expression and overall survival in gastric cancer patients. Asian Pac. J. Cancer Prev. 2014, 15, 6935–6938. [Google Scholar] [CrossRef]
- Lage, H. Molecular analysis of therapy resistance in gastric cancer. Dig. Dis. 2003, 21, 326–338. [Google Scholar] [CrossRef]
- Prime-Chapman, H.M.; Fearn, R.A.; Cooper, A.E.; Moore, V.; Hirst, B.H. Differential multidrug resistance-associated protein 1 through 6 isoform expression and function in human intestinal epithelial Caco-2 cells. J. Pharm. Exp. 2004, 311, 476–484. [Google Scholar] [CrossRef]
- Al-Abdulla, R.; Perez-Silva, L.; Lozano, E.; Macias, R.I.R.; Herraez, E.; Abad, M.; Segues, N.; Bujanda, L.; Briz, O.; Marin, J.J.G. Sensitizing gastric adenocarcinoma to chemotherapy by pharmacological manipulation of drug transporters. Biochem. Pharm. 2020, 171, 113682. [Google Scholar] [CrossRef] [PubMed]
- Lacueva, J.; Perez-Ramos, M.; Soto, J.L.; Oliver, I.; Andrada, E.; Medrano, J.; Perez-Vazquez, T.; Arroyo, A.; Carrato, A.; Ferragut, J.A.; et al. Multidrug resistance-associated protein (MRP1) gene is strongly expressed in gastric carcinomas. Analysis by immunohistochemistry and real-time quantitative RT-PCR. Histopathology 2005, 46, 389–395. [Google Scholar] [CrossRef] [PubMed]
- Alexander, D.; Yamamoto, T.; Kato, S.; Kasai, S. Histopathological assessment of multidrug resistance in gastric cancer: Expression of P-glycoprotein, multidrug resistance-associated protein, and lung-resistance protein. Surg. Today 1999, 29, 401–406. [Google Scholar] [CrossRef] [PubMed]
- Obuchi, W.; Ohtsuki, S.; Uchida, Y.; Ohmine, K.; Yamori, T.; Terasaki, T. Identification of transporters associated with Etoposide sensitivity of stomach cancer cell lines and methotrexate sensitivity of breast cancer cell lines by quantitative targeted absolute proteomics. Mol. Pharm. 2013, 83, 490–500. [Google Scholar] [CrossRef]
- Zhang, X.; Bo, P.; Liu, L.; Zhang, X.; Li, J. Overexpression of long non-coding RNA GHET1 promotes the development of multidrug resistance in gastric cancer cells. Biomed. Pharmacother. 2017, 92, 580–585. [Google Scholar] [CrossRef]
- Xu, Y.D.; Shang, J.; Li, M.; Zhang, Y.Y. LncRNA DANCR accelerates the development of multidrug resistance of gastric cancer. Eur. Rev. Med. Pharmacol. Sci. 2019, 23, 2794–2802. [Google Scholar] [CrossRef]
- Sandusky, G.E.; Mintze, K.S.; Pratt, S.E.; Dantzig, A.H. Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology 2002, 41, 65–74. [Google Scholar] [CrossRef]
- Narasaki, F.; Oka, M.; Nakano, R.; Ikeda, K.; Fukuda, M.; Nakamura, T.; Soda, H.; Nakagawa, M.; Kuwano, M.; Kohno, S. Human canalicular multispecific organic anion transporter (cMOAT) is expressed in human lung, gastric, and colorectal cancer cells. Biochem. Biophys. Res. Commun. 1997, 240, 606–611. [Google Scholar] [CrossRef]
- Chen, X.; Zhang, M.; Liu, L.X. The overexpression of multidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells. Oncol. Rep. 2009, 22, 73–80. [Google Scholar]
- Gotovdorj, T.; Lee, E.; Lim, Y.; Cha, E.J.; Kwon, D.; Hong, E.; Kim, Y.; Oh, M.Y. 2,3,7,8-Tetrachlorodibenzo-p-dioxin induced cell-specific drug transporters with acquired cisplatin resistance in cisplatin sensitive cancer cells. J. Korean Med. Sci. 2014, 29, 1188–1198. [Google Scholar] [CrossRef]
- Wu, Q.; Li, Z.S.; Li, D.W.; Peng, Z.H.; Yang, Z.R. [Relationship between the expression of hypoxia-inducible factor-1alpha and chemotherapy response in gastric carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi = Chin. J. Gastrointest. Surg. 2009, 12, 498–501. [Google Scholar]
- Diestra, J.E.; Scheffer, G.L.; Catala, I.; Maliepaard, M.; Schellens, J.H.; Scheper, R.J.; Germa-Lluch, J.R.; Izquierdo, M.A. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J. Pathol. 2002, 198, 213–219. [Google Scholar] [CrossRef] [PubMed]
- Zhan, D.; Ni, T.; Wang, H.; Lv, M.; Sunagawa, M.; Liu, Y. Celastrol inhibits the proliferation and decreases drug resistance of cisplatin- resistant gastric cancer SGC7901/DDP cells. Anti-Cancer Agents Med. Chem. 2022, 22, 270–279. [Google Scholar] [CrossRef] [PubMed]
- Huang, W.; Wan, C.; Luo, Q.; Huang, Z.; Luo, Q. Genistein-inhibited cancer stem cell-like properties and reduced chemoresistance of gastric cancer. Int. J. Mol. Sci. 2014, 15, 3432–3443. [Google Scholar] [CrossRef] [PubMed]
- Kowalski, P.; Stein, U.; Scheffer, G.L.; Lage, H. Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2. Cancer Gene Ther. 2002, 9, 579–586. [Google Scholar] [CrossRef]
- Conroy, T.; Desseigne, F.; Ychou, M.; Bouche, O.; Guimbaud, R.; Becouarn, Y.; Adenis, A.; Raoul, J.L.; Gourgou-Bourgade, S.; de la Fouchardiere, C.; et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011, 364, 1817–1825. [Google Scholar] [CrossRef]
- Quinonero, F.; Mesas, C.; Doello, K.; Cabeza, L.; Perazzoli, G.; Jimenez-Luna, C.; Rama, A.R.; Melguizo, C.; Prados, J. The challenge of drug resistance in pancreatic ductal adenocarcinoma: A current overview. Cancer Biol. Med. 2019, 16, 688–699. [Google Scholar] [CrossRef]
- Chen, M.; Xue, X.; Wang, F.; An, Y.; Tang, D.; Xu, Y.; Wang, H.; Yuan, Z.; Gao, W.; Wei, J.; et al. Expression and promoter methylation analysis of ATP-binding cassette genes in pancreatic cancer. Oncol. Rep. 2012, 27, 265–269. [Google Scholar] [CrossRef]
- Song, B.; Liu, X.S.; Rice, S.J.; Kuang, S.; Elzey, B.D.; Konieczny, S.F.; Ratliff, T.L.; Hazbun, T.; Chiorean, E.G.; Liu, X. Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer. Mol. Cancer 2013, 12, 58–68. [Google Scholar] [CrossRef]
- Ouyang, L.; Liu, R.D.; Lei, D.Q.; Shang, Q.C.; Li, H.F.; Hu, X.G.; Zheng, H.; Jin, G. MiR-499a-5p promotes 5-FU resistance and the cell proliferation and migration through activating PI3K/Akt signaling by targeting PTEN in pancreatic cancer. Ann. Transl. Med. 2021, 9, 1798. [Google Scholar] [CrossRef]
- Gu, J.; Huang, W.; Wang, X.; Zhang, J.; Tao, T.; Zheng, Y.; Liu, S.; Yang, J.; Chen, Z.S.; Cai, C.Y.; et al. Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer. Mol. Cancer 2022, 21, 112. [Google Scholar] [CrossRef] [PubMed]
- Wei, L.; Lin, Q.; Lu, Y.; Li, G.; Huang, L.; Fu, Z.; Chen, R.; Zhou, Q. Cancer-associated fibroblasts-mediated ATF4 expression promotes malignancy and gemcitabine resistance in pancreatic cancer via the TGF-beta1/SMAD2/3 pathway and ABCC1 transactivation. Cell Death Dis. 2021, 12, 334. [Google Scholar] [CrossRef] [PubMed]
- Tanaka, M.; Okazaki, T.; Suzuki, H.; Abbruzzese, J.L.; Li, D. Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome. Cancer 2011, 117, 744–751. [Google Scholar] [CrossRef] [PubMed]
- Horiguchi, S.; Shiraha, H.; Nagahara, T.; Kataoka, J.; Iwamuro, M.; Matsubara, M.; Nishina, S.; Kato, H.; Takaki, A.; Nouso, K.; et al. Loss of runt-related transcription factor 3 induces gemcitabine resistance in pancreatic cancer. Mol. Oncol. 2013, 7, 840–849. [Google Scholar] [CrossRef]
- Hagmann, W.; Jesnowski, R.; Faissner, R.; Guo, C.; Lohr, J.M. ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology 2009, 9, 136–144. [Google Scholar] [CrossRef]
- Adamska, A.; Ferro, R.; Lattanzio, R.; Capone, E.; Domenichini, A.; Damiani, V.; Chiorino, G.; Akkaya, B.G.; Linton, K.J.; De Laurenzi, V.; et al. ABCC3 is a novel target for the treatment of pancreatic cancer. Adv. Biol. Regul. 2019, 73, 100634. [Google Scholar] [CrossRef]
- Nambaru, P.K.; Hubner, T.; Kock, K.; Mews, S.; Grube, M.; Payen, L.; Guitton, J.; Sendler, M.; Jedlitschky, G.; Rimmbach, C.; et al. Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil. Drug Metab. Dispos. 2011, 39, 132–139. [Google Scholar] [CrossRef]
- Hagmann, W.; Faissner, R.; Schnolzer, M.; Lohr, M.; Jesnowski, R. Membrane drug transporters and chemoresistance in human pancreatic carcinoma. Cancers 2010, 3, 106–125. [Google Scholar] [CrossRef]
- Hagmann, W.; Jesnowski, R.; Lohr, J.M. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia 2010, 12, 740–747. [Google Scholar] [CrossRef]
- Lee, S.H.; Kim, H.; Hwang, J.H.; Lee, H.S.; Cho, J.Y.; Yoon, Y.S.; Han, H.S. Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients. Pathol. Int. 2012, 62, 167–175. [Google Scholar] [CrossRef]
- Lu, Z.; Kleeff, J.; Shrikhande, S.; Zimmermann, T.; Korc, M.; Friess, H.; Buchler, M.W. Expression of the multidrug-resistance 1 (MDR1) gene and prognosis in human pancreatic cancer. Pancreas 2000, 21, 240–247. [Google Scholar] [CrossRef] [PubMed]
- Suwa, H.; Ohshio, G.; Arao, S.; Imamura, T.; Yamaki, K.; Manabe, T.; Imamura, M.; Hiai, H.; Fukumoto, M. Immunohistochemical localization of P-glycoprotein and expression of the multidrug resistance-1 gene in human pancreatic cancer: Relevance to indicator of better prognosis. Jpn. J. Cancer Res. 1996, 87, 641–649. [Google Scholar] [CrossRef] [PubMed]
- Harpstrite, S.E.; Gu, H.; Natarajan, R.; Sharma, V. Interrogation of multidrug resistance (MDR1) P-glycoprotein (ABCB1) expression in human pancreatic carcinoma cells: Correlation of 99mTc-Sestamibi uptake with western blot analysis. Nucl. Med. Commun. 2014, 35, 1067–1070. [Google Scholar] [CrossRef] [PubMed]
- Zhao, Y.P.; Zhang, L.Y.; Liao, Q.; Guo, J.C.; Chen, G.; Li, J.Y. Detection of multidrug resistant gene 1 in pancreatic cancer. Hepatobiliary Pancreat. Dis. Int. 2004, 3, 307–310. [Google Scholar] [PubMed]
- Liu, B.; Staren, E.D.; Iwamura, T.; Appert, H.E.; Howard, J.M. Mechanisms of taxotere-related drug resistance in pancreatic carcinoma. J. Surg. Res. 2001, 99, 179–186. [Google Scholar] [CrossRef]
- Hong, S.P.; Wen, J.; Bang, S.; Park, S.; Song, S.Y. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int. J. Cancer 2009, 125, 2323–2331. [Google Scholar] [CrossRef]
- Konig, J.; Hartel, M.; Nies, A.T.; Martignoni, M.E.; Guo, J.; Buchler, M.W.; Friess, H.; Keppler, D. Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int. J. Cancer 2005, 115, 359–367. [Google Scholar] [CrossRef]
- Mohelnikova-Duchonova, B.; Brynychova, V.; Oliverius, M.; Honsova, E.; Kala, Z.; Muckova, K.; Soucek, P. Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and nonneoplastic tissues. Pancreas 2013, 42, 707–716. [Google Scholar] [CrossRef]
- Cao, J.; Yang, J.; Ramachandran, V.; Arumugam, T.; Deng, D.; Li, Z.; Xu, L.; Logsdon, C.D. TM4SF1 promotes gemcitabine resistance of pancreatic cancer in vitro and in vivo. PLoS ONE 2015, 10, e0144969. [Google Scholar] [CrossRef]
- Noma, B.; Sasaki, T.; Fujimoto, Y.; Serikawa, M.; Kobayashi, K.; Inoue, M.; Itsuki, H.; Kamigaki, M.; Minami, T.; Chayama, K. Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer. Int. J. Oncol. 2008, 33, 1187–1194. [Google Scholar] [CrossRef]
- Zhang, Z.; Wang, J.; Shen, B.; Peng, C.; Zheng, M. The ABCC4 gene is a promising target for pancreatic cancer therapy. Gene 2012, 491, 194–199. [Google Scholar] [CrossRef] [PubMed]
- Carozzo, A.; Diez, F.; Gomez, N.; Cabrera, M.; Shayo, C.; Davio, C.; Fernandez, N. Dual role of cAMP in the transcriptional regulation of multidrug resistance-associated protein 4 (MRP4) in pancreatic adenocarcinoma cell lines. PLoS ONE 2015, 10, e0120651. [Google Scholar] [CrossRef] [PubMed]
- Kramer, R.; Weber, T.K.; Morse, B.; Arceci, R.; Staniunas, R.; Steele, G., Jr.; Summerhayes, I.C. Constitutive expression of multidrug resistance in human colorectal tumours and cell lines. Br. J. Cancer 1993, 67, 959–968. [Google Scholar] [CrossRef]
- Marin, J.J.G.; Macias, R.I.R.; Monte, M.J.; Herraez, E.; Peleteiro-Vigil, A.; Blas, B.S.; Sanchon-Sanchez, P.; Temprano, A.G.; Espinosa-Escudero, R.A.; Lozano, E.; et al. Cellular mechanisms accounting for the refractoriness of colorectal carcinoma to pharmacological treatment. Cancers 2020, 12, 2605. [Google Scholar] [CrossRef] [PubMed]
- Wilson, B.J.; Schatton, T.; Zhan, Q.; Gasser, M.; Ma, J.; Saab, K.R.; Schanche, R.; Waaga-Gasser, A.M.; Gold, J.S.; Huang, Q.; et al. ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. Cancer Res. 2011, 71, 5307–5316. [Google Scholar] [CrossRef] [PubMed]
- Cao, D.; Qin, S.; Mu, Y.; Zhong, M. The role of MRP1 in the multidrug resistance of colorectal cancer. Oncol. Lett. 2017, 13, 2471–2476. [Google Scholar] [CrossRef]
- Gao, R.; Fang, C.; Xu, J.; Tan, H.; Li, P.; Ma, L. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145. Arch. Biochem. Biophys. 2019, 663, 183–191. [Google Scholar] [CrossRef]
- Abdallah, E.A.; Fanelli, M.F.; Souza, E.S.V.; Machado Netto, M.C.; Gasparini Junior, J.L.; Araujo, D.V.; Ocea, L.M.; Buim, M.E.; Tariki, M.S.; Alves Vda, S.; et al. MRP1 expression in CTCs confers resistance to irinotecan-based chemotherapy in metastatic colorectal cancer. Int. J. Cancer 2016, 139, 890–898. [Google Scholar] [CrossRef]
- Labriet, A.; Levesque, E.; De Mattia, E.; Cecchin, E.; Jonker, D.; Couture, F.; Simonyan, D.; Buonadonna, A.; D’Andrea, M.; Villeneuve, L.; et al. Combination of germline variations associated with survival of folinic acid, fluorouracil and irinotecan-treated metastatic colorectal cancer patients. Pharmacogenomics 2019, 20, 1179–1187. [Google Scholar] [CrossRef]
- Hinoshita, E.; Uchiumi, T.; Taguchi, K.; Kinukawa, N.; Tsuneyoshi, M.; Maehara, Y.; Sugimachi, K.; Kuwano, M. Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin. Cancer Res. 2000, 6, 2401–2407. [Google Scholar]
- Koike, K.; Kawabe, T.; Tanaka, T.; Toh, S.; Uchiumi, T.; Wada, M.; Akiyama, S.; Ono, M.; Kuwano, M. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res. 1997, 57, 5475–5479. [Google Scholar] [PubMed]
- Dong, Y.; Wang, Z.; Xie, G.F.; Li, C.; Zuo, W.W.; Meng, G.; Xu, C.P.; Li, J.J. Pregnane X receptor is associated with unfavorable survival and induces chemotherapeutic resistance by transcriptional activating multidrug resistance-related protein 3 in colorectal cancer. Mol. Cancer 2017, 16, 71. [Google Scholar] [CrossRef] [PubMed]
- Kobayashi, M.; Funayama, R.; Ohnuma, S.; Unno, M.; Nakayama, K. Wnt-beta-catenin signaling regulates ABCC3 (MRP3) transporter expression in colorectal cancer. Cancer Sci. 2016, 107, 1776–1784. [Google Scholar] [CrossRef] [PubMed]
- Chen, Q.; Meng, F.; Wang, L.; Mao, Y.; Zhou, H.; Hua, D.; Zhang, H.; Wang, W. A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patients. Sci. Rep. 2017, 7, 7059. [Google Scholar] [CrossRef] [PubMed]
- Ma, L.; Liu, T.; Jin, Y.; Wei, J.; Yang, Y.; Zhang, H. ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells. Tumour Biol. 2016, 37, 12889–12896. [Google Scholar] [CrossRef]
- Mizoguchi, T.; Yamada, K.; Furukawa, T.; Hidaka, K.; Hisatsugu, T.; Shimazu, H.; Tsuruo, T.; Sumizawa, T.; Akiyama, S. Expression of the MDR1 gene in human gastric and colorectal carcinomas. J. Natl. Cancer Inst. 1990, 82, 1679–1683. [Google Scholar] [CrossRef]
- Pirker, R.; Wallner, J.; Gsur, A.; Gotzl, M.; Zochbauer, S.; Scheithauer, W.; Depisch, D. MDR1 gene expression in primary colorectal carcinomas. Br. J. Cancer 1993, 68, 691–694. [Google Scholar] [CrossRef]
- Iyer, L.; Ramirez, J.; Shepard, D.R.; Bingham, C.M.; Hossfeld, D.K.; Ratain, M.J.; Mayer, U. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother. Pharm. 2002, 49, 336–341. [Google Scholar] [CrossRef]
- Micsik, T.; Lorincz, A.; Mersich, T.; Baranyai, Z.; Besznyak, I., Jr.; Dede, K.; Zarand, A.; Jakab, F.; Szollosi, L.K.; Keri, G.; et al. Decreased functional activity of multidrug resistance protein in primary colorectal cancer. Diagn. Pathol. 2015, 10, 26. [Google Scholar] [CrossRef]
- Efferth, T.; Konkimalla, V.B.; Wang, Y.F.; Sauerbrey, A.; Meinhardt, S.; Zintl, F.; Mattern, J.; Volm, M. Prediction of broad spectrum resistance of tumors towards anticancer drugs. Clin. Cancer Res. 2008, 14, 2405–2412. [Google Scholar] [CrossRef]
- Nishioka, C.; Sakaeda, T.; Nakamura, T.; Moriya, Y.; Okamura, N.; Tamura, T.; Nakahara, T.; Aoyama, N.; Kamigaki, T.; Ohno, M.; et al. MDR1, MRP1 and MRP2 genotypes and in vitro chemosensitivity in Japanese patients with colorectal adenocarcinomas. Kobe J. Med. Sci. 2004, 50, 181–188. [Google Scholar] [PubMed]
- Yang, J.; Song, P.; Zhou, G. A study on the correlations of MRP-1 expression with the pathogenesis and prognosis of colorectal cancer. J. BUON 2019, 24, 84–90. [Google Scholar] [PubMed]
- Huang, W.; Zhang, H.; Tian, Y.; Li, Y.; Li, J.; Zhong, X.; Yuan, X. LncRNA SNHG11 enhances bevacizumab resistance in colorectal cancer by mediating miR-1207-5p/ABCC1 axis. Anti-Cancer Drugs 2022, 33, 575–586. [Google Scholar] [CrossRef] [PubMed]
- Silva, V.S.E.; Abdallah, E.A.; Brito, A.B.C.; Braun, A.C.; Tariki, M.S.; de Mello, C.A.L.; Calsavara, V.F.; Riechelmann, R.; Chinen, L.T.D. Baseline and kinetic circulating tumor cell counts are prognostic factors in a prospective study of metastatic colorectal cancer. Diagnostics 2021, 11, 502. [Google Scholar] [CrossRef]
- Wang, Z.; Sun, X.; Feng, Y.; Liu, X.; Zhou, L.; Sui, H.; Ji, Q.; E, Q.; Chen, J.; Wu, L.; et al. Dihydromyricetin reverses MRP2-mediated MDR and enhances anticancer activity induced by oxaliplatin in colorectal cancer cells. Anti-Cancer Drugs 2017, 28, 281–288. [Google Scholar] [CrossRef]
- Monte, M.J.; Ballestero, M.R.; Briz, O.; Perez, M.J.; Marin, J.J. Proapoptotic effect on normal and tumor intestinal cells of cytostatic drugs with enterohepatic organotropism. J. Pharm. Exp. 2005, 315, 24–35. [Google Scholar] [CrossRef]
- Martinez-Becerra, P.; Monte, I.; Romero, M.R.; Serrano, M.A.; Vaquero, J.; Macias, R.I.; Del Rio, A.; Grane-Boladeras, N.; Jimenez, F.; San-Martin, F.G.; et al. Up-regulation of FXR isoforms is not required for stimulation of the expression of genes involved in the lack of response of colon cancer to chemotherapy. Pharm. Res. 2012, 66, 419–427. [Google Scholar] [CrossRef]
- Herraez, E.; Gonzalez-Sanchez, E.; Vaquero, J.; Romero, M.R.; Serrano, M.A.; Marin, J.J.; Briz, O. Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins. Mol. Pharm. 2012, 9, 2565–2576. [Google Scholar] [CrossRef]
- Ballestero, M.R.; Monte, M.J.; Briz, O.; Jimenez, F.; Gonzalez-San Martin, F.; Marin, J.J. Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. Biochem. Pharm. 2006, 72, 729–738. [Google Scholar] [CrossRef]
- Park, G.B.; Chung, Y.H.; Kim, D. 2-Deoxy-D-glucose suppresses the migration and reverses the drug resistance of colon cancer cells through ADAM expression regulation. Anti-Cancer Drugs 2017, 28, 410–420. [Google Scholar] [CrossRef]
- Holla, V.R.; Backlund, M.G.; Yang, P.; Newman, R.A.; DuBois, R.N. Regulation of prostaglandin transporters in colorectal neoplasia. Cancer Prev. Res. 2008, 1, 93–99. [Google Scholar] [CrossRef] [PubMed]
- Pereira, C.; Queiros, S.; Galaghar, A.; Sousa, H.; Pimentel-Nunes, P.; Brandao, C.; Moreira-Dias, L.; Medeiros, R.; Dinis-Ribeiro, M. Genetic variability in key genes in prostaglandin E2 pathway (COX-2, HPGD, ABCC4 and SLCO2A1) and their involvement in colorectal cancer development. PLoS ONE 2014, 9, e92000. [Google Scholar] [CrossRef] [PubMed]
- Gradilone, A.; Pulcinelli, F.M.; Lotti, L.V.; Trifiro, E.; Martino, S.; Gandini, O.; Gianni, W.; Frati, L.; Agliano, A.M.; Gazzaniga, P. Celecoxib upregulates multidrug resistance proteins in colon cancer: Lack of synergy with standard chemotherapy. Curr. Cancer. Drug Targets 2008, 8, 414–420. [Google Scholar] [CrossRef] [PubMed]
- Di Martino, M.T.; Arbitrio, M.; Leone, E.; Guzzi, P.H.; Rotundo, M.S.; Ciliberto, D.; Tomaino, V.; Fabiani, F.; Talarico, D.; Sperlongano, P.; et al. Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: A DMET microarray profiling study. Cancer Biol. Ther. 2011, 12, 780–787. [Google Scholar] [CrossRef] [PubMed]
- Wijnholds, J.; Mol, C.A.; van Deemter, L.; de Haas, M.; Scheffer, G.L.; Baas, F.; Beijnen, J.H.; Scheper, R.J.; Hatse, S.; De Clercq, E.; et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc. Natl. Acad. Sci. USA 2000, 97, 7476–7481. [Google Scholar] [CrossRef]
- Chen, K.; Huang, Y.H.; Chen, J.L. Understanding and targeting cancer stem cells: Therapeutic implications and challenges. Acta Pharm. Sin. 2013, 34, 732–740. [Google Scholar] [CrossRef]
- Ross, D.D.; Yang, W.; Abruzzo, L.V.; Dalton, W.S.; Schneider, E.; Lage, H.; Dietel, M.; Greenberger, L.; Cole, S.P.; Doyle, L.A. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J. Natl. Cancer Inst. 1999, 91, 429–433. [Google Scholar] [CrossRef]
Pharmacological Groups | Drugs | Cancers | ABC Pumps | ||
---|---|---|---|---|---|
Alkylating Drugs | Cyclophosphamide | HB | MRP1, 4 | ||
Anthracyclines | Doxorubicin | GAC, HB, HCC | MDR1 | MRP1, 2, 6 | BCRP |
Camptothecins | Irinotecan | BTC, CRC, GAC, HB, PDAC | MDR1 | MRP1, 2, 4, 6 | BCRP |
TKIs | Sorafenib | HCC | MDR1 | MRP1, 2, 3 | BCRP |
Regorafenib | CRC, HCC | MDR1 | MRP2 | ||
Lenvatinib | HCC | MDR1 | MRP2 | ||
Cabozantinib | HCC | MDR1 | MRP2 | ||
Platinum Derivatives | Cisplatin | BTC, GAC, HB, HCC | MRP2, 6 | ||
Oxaliplatin | BTC, CRC, GAC, PDAC | MRP2, 6 | |||
Podophyllotoxins | Etoposide | BTC, HB | MDR1 | MRP1, 2 | |
Pyrimidines | 5-FU | BTC, CRC, GAC, HB, HCC, PDAC | MRP1, 4, 5 | BCRP | |
Gemcitabine | BTC, PDAC | MDR1 | MRP2, 4, 5, 6 | ||
Taxanes | Docetaxel | GAC | MDR1 | MRP1 | |
Vinca Alkaloids | Vinblastine | HB | MDR1 | MRP1, 2 |
Change | Drugs Affected | Impact | Ref. |
---|---|---|---|
MDR1 upregulation | Sorafenib | Reduced OS | [8,9] |
Doxorubicin | Worse prognosis | [10] | |
MDR1 variant rs1045642 | Sorafenib | Better clinical evolution | [11] |
ABCB5 upregulation | Doxorubicin | Decreased cell sensitivity in vitro | [12] |
MRP1 upregulation | Sorafenib | Worse response | [13] |
MRP2 upregulation | Sorafenib | Decreased cell sensitivity in vitro | [14] |
MRP3 upregulation | Sorafenib | Decreased cell sensitivity in vitro | [15] |
MRP4 upregulation | Cisplatin | Decreased cell sensitivity in vitro | [16] |
MRP5 upregulation | 5-FU, cisplatin, doxorubicin | Decreased cell sensitivity in vitro | [17,18,19] |
BCRP upregulation | Doxorubicin | Decreased cell sensitivity in vitro | [20] |
Sorafenib | Worse response | [9,21] | |
BCRP variants rs2231137 and rs2231142 | Sorafenib | Better clinical evolution | [11] |
ABCF1 upregulation | Cisplatin, doxorubicin | Decreased cell sensitivity in vitro and in vivo | [22] |
Change | Drugs Affected | Impact | Ref. |
---|---|---|---|
MDR1 upregulation | Gemcitabine | Reduced response | [60] |
MRP1 upregulation | 5-FU, Gemcitabine | Decreased cell sensitivity in vitro | [61,62] |
Cisplatin, Gemcitabine | Worse prognosis | [63,64] | |
MRP3 downregulation | 5-FU | Increased cell sensitivity in vitro | [65] |
MRP5 downregulation | Gemcitabine | Increased cell sensitivity in vitro | [66] |
MRP6 downregulation | Gemcitabine | Increased cell sensitivity in vitro | [66] |
MDR1, MRP3, and BCRP upregulation | 5-FU | Reduced response | [67] |
Protein Change | Drugs Affected | Impact | Ref. |
---|---|---|---|
MDR1 upregulation | Doxorubicin | Decreased cell sensitivity in vitro | [89] |
MRP1 upregulation | Doxorubicin | Reduced response | [33] |
MRP2 upregulation | Cisplatin | Reduced response | [90] |
Change | Drugs Affected | Impact | Ref. |
---|---|---|---|
MDR1 upregulation | Cisplatin, epirubicin | Worse response | [114,115] |
Cisplatin, oxaliplatin, epirubicin | Decreased cell sensitivity in vitro | [116,117,118] | |
MRP1 upregulation | Cisplatin | Worse response | [119] |
MRP4 downregulation | 5-FU | Increased cell sensitivity in vitro | [120] |
Cisplatin | Increased cell sensitivity in vitro | [121] | |
MRP4 upregulation | Dasatinib | Decreased cell sensitivity in vitro and in vivo | [122] |
BCRP upregulation | Cisplatin, 5-FU | Reduced OS | [123,124] |
Change | Drugs Affected | Impact | Ref. |
---|---|---|---|
MDR1 upregulation | Gemcitabine | Decreased cell sensitivity in vitro | [149,150] |
MRP1 upregulation | 5-FU | Decreased cell sensitivity in vitro | [151,152] |
MRP1 downregulation | Gemcitabine | Increased cell sensitivity in vitro | [153] |
MRP2 upregulation | Gemcitabine | Reduced OS | [154] |
MRP2 downregulation | Gemcitabine | Increased cell sensitivity in vitro | [79,155] |
MRP3 upregulation | 5-FU | Decreased cell sensitivity in vitro | [156,157] |
MRP4 upregulation | 5-FU | Decreased cell sensitivity in vitro | [156] |
MRP5 upregulation | 5-FU | Decreased cell sensitivity in vitro | [158] |
Gemcitabine | Decreased cell sensitivity in vitro | [159,160] | |
BCRP upregulation | Gemcitabine | Worse prognosis | [161] |
Change | Drugs Affected | Impact | Ref. |
---|---|---|---|
MDR1 upregulation | Doxorubicin, vincristine | Decreased cell sensitivity in vitro | [174] |
ABCB5 upregulation | 5-FU | Worse response | [176] |
MRP1 upregulation | 5-FU, oxaliplatin | Decreased cell sensitivity in vitro | [177,178] |
Irinotecan | Worse response | [179] | |
MRP1 variant rs17501011 | 5-FU, irinotecan | Reduced OS | [180] |
MRP2 upregulation | Cisplatin | Worse response | [181] |
Cisplatin | Decreased cell sensitivity in vitro | [182] | |
MRP3 upregulation | Etoposide, oxaliplatin | Decreased cell sensitivity in vitro | [183,184] |
MRP4 variant rs3742106 | 5-FU | Worse response | [185] |
MRP5 upregulation | 5-FU, doxorubicin, cisplatin, oxaliplatin | Decreased cell sensitivity in vitro | [104] |
BCRP downregulation | 5-FU, oxaliplatin | Increased cell sensitivity in vitro | [186] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Marin, J.J.G.; Monte, M.J.; Macias, R.I.R.; Romero, M.R.; Herraez, E.; Asensio, M.; Ortiz-Rivero, S.; Cives-Losada, C.; Di Giacomo, S.; Gonzalez-Gallego, J.; et al. Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers. Cancers 2022, 14, 3524. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14143524
Marin JJG, Monte MJ, Macias RIR, Romero MR, Herraez E, Asensio M, Ortiz-Rivero S, Cives-Losada C, Di Giacomo S, Gonzalez-Gallego J, et al. Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers. Cancers. 2022; 14(14):3524. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14143524
Chicago/Turabian StyleMarin, Jose J. G., Maria J. Monte, Rocio I. R. Macias, Marta R. Romero, Elisa Herraez, Maitane Asensio, Sara Ortiz-Rivero, Candela Cives-Losada, Silvia Di Giacomo, Javier Gonzalez-Gallego, and et al. 2022. "Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers" Cancers 14, no. 14: 3524. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14143524